Skip to main content

Advertisement

SpringerLink
Log in

HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study)

  • Original Paper
  • Published:
AIDS and Behavior Aims and scope Submit manuscript

Abstract

In Western countries, tobacco smoking is highly prevalent among patients co-infected with HIV and hepatitis C virus (HCV). In the era of antiretrovirals and HCV cure, smoking-related health damages contribute greatly to morbidity and mortality in HIV-HCV co-infected patients. We used longitudinal data from the ANRS CO13 HEPAVIH cohort to identify the correlates of tobacco smoking quit attempts (TSQA) in HIV-HCV co-infected patients. TSQA were modelled using a multivariable discrete-time Cox proportional hazards model in 695 HIV-HCV co-infected tobacco smokers. HCV cure was associated with a 76% higher chance of TSQA (adjusted hazard ratio [95% confidence interval]: 1.76 [1.06–2.93], p = 0.029), and cannabis use with a 37% lower chance (0.63 [0.40–1.00], p = 0.049), independently of the mode of HIV transmission, other psychoactive substance use, and body mass index. Patients should be screened for tobacco and cannabis use at HCV treatment initiation and during follow-up. They should also be provided with comprehensive counselling and referral to addiction services. Non-smoking routes of cannabis administration should be promoted for cannabis users who wish to quit smoking tobacco.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Park LS, Hernández-Ramírez RU, Silverberg MJ, Crothers K, Dubrow R. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS Lond Engl. 2016;30(2):273–91.

    CAS  Google Scholar 

  2. Tron L, Lert F, Spire B, Dray-Spira R. Tobacco smoking in HIV-infected versus general population in france: heterogeneity across the various groups of people living with HIV. PLoS ONE. 2014;9(9):e107451.

    PubMed  PubMed Central  Google Scholar 

  3. Conseil national du SIDA et des hépatites virales (CNS), Agence nationale de recherche sur le sida et les hépatites virales (ANRS). Epidémiologie de l’infection à VIH en France (juillet 2017) [Epidemiology of HIV infection in France]. CNS/ANRS. https://cns.sante.fr/wp-content/uploads/2017/10/experts-vih_epidemio.pdf (2017). Accessed 10 June 2020

  4. Andler R, Richard J-B, Guignard R, Quatremère G, Verrier F, Gane J, et al. Reduction of daily smoking rate among adults: results from the 2018 Santé Publique France health barometer. Bull Epidémiol Hebd. 2019;15:271–7.

    Google Scholar 

  5. Reynolds NR. Cigarette smoking and hiv: more evidence for action. AIDS Educ Prev Off Publ Int Soc AIDS Educ. 2009;21(3 Suppl):106–21.

    Google Scholar 

  6. Marshall MM, Kirk GD, Caporaso NE, McCormack MC, Merlo CA, Hague JC, et al. Tobacco use and nicotine dependence among HIV-infected and uninfected injection drug users. Addict Behav. 2010;36(1–2):61–7.

    PubMed  PubMed Central  Google Scholar 

  7. McKirnan DJ, Tolou-Shams M, Turner L, Dyslin K, Hope B. Elevated risk for tobacco use among men who have sex with men is mediated by demographic and psychosocial variables. Subst Use Misuse. 2006;41(8):1197–208.

    PubMed  Google Scholar 

  8. Barré T, Nishimwe ML, Protopopescu C, Marcellin F, Carrat F, Dorival C, et al. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort). J Viral Hepat. 2020;27(12):1473–83.

    PubMed  Google Scholar 

  9. Kim RS, Weinberger AH, Chander G, Sulkowski MS, Norton B, Shuter J. Cigarette smoking in persons living with hepatitis C: the National Health and Nutrition Examination Survey (NHANES), 1999–2014. Am J Med. 2018;131(6):669–75.

    PubMed  PubMed Central  Google Scholar 

  10. Chew KW, Bhattacharya D, McGinnis KA, Horwich TB, Tseng C-H, Currier JS, et al. Short communication: coronary heart disease risk by framingham risk score in hepatitis C and HIV/Hepatitis C-coinfected persons. AIDS Res Hum Retroviruses. 2015;31(7):718–22.

    PubMed  PubMed Central  Google Scholar 

  11. Knight R, Roux P, Vilotitch A, Marcellin F, Rosenthal E, Esterle L, et al. Significant reductions in alcohol use after Hepatitis C treatment: results from the French ANRS CO13-HEPAVIH cohort: significant reductions in alcohol use. Addiction. 2017;112:1669.

    PubMed  Google Scholar 

  12. Fialho R, Pereira M, Rusted J, Whale R. Depression in HIV and HCV co-infected patients: a systematic review and meta-analysis. Psychol Health Med. 2017;22(9):1089–104.

    PubMed  Google Scholar 

  13. Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, et al. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int Off J Int Assoc Study Liver. 2015;35(1):65–70.

    Google Scholar 

  14. Hagan H, Thiede H, Des Jarlais DC. HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS Lond Engl. 2005;19(Suppl 3):S199-207.

    Google Scholar 

  15. Kariuki W, Manuel JI, Kariuki N, Tuchman E, O’Neal J, Lalanne GA. HIV and smoking: associated risks and prevention strategies. HIVAIDS (Auckland, NZ). 2015;8:17–36.

    Google Scholar 

  16. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet Lond Engl. 2008;372(9635):293–9.

    Google Scholar 

  17. Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS Lond Engl. 2014;28(8):1181–91.

    Google Scholar 

  18. Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, et al. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS Lond Engl. 2015;29(2):221–9.

    CAS  Google Scholar 

  19. Gartner C, Miller A, Bonevski B. Extending survival for people with hepatitis C using tobacco dependence treatment. Lancet. 2017;390(10107):2033.

    PubMed  Google Scholar 

  20. Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, et al. Trends in cause-specific mortality in HIV–hepatitis C coinfection following hepatitis C treatment scale-up. AIDS. 2019;33(6):1013.

    PubMed  Google Scholar 

  21. Caven M, Malaguti A, Robinson E, Fletcher E, Dillon JF. Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: a systematic review. Int J Drug Policy. 2019;72:169–76.

    PubMed  Google Scholar 

  22. Yeung MW, Young J, Moodie E, Rollet-Kurhajec KC, Schwartzman K, Greenaway C, et al. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study. HIV Clin Trials. 2015;16(3):100–10.

    PubMed  Google Scholar 

  23. Loko M-A, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006–2010. BMC Infect Dis. 2010;10:303.

    PubMed  PubMed Central  Google Scholar 

  24. Prentiss D, Power R, Balmas G, Tzuang G, Israelski D. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr. 1999;2004(35):38–45.

    Google Scholar 

  25. Fischer B, Reimer J, Firestone M, Kalousek K, Rehm J, Heathcote J. Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions. Eur J Gastroenterol Hepatol. 2006;18(10):1039–42.

    PubMed  Google Scholar 

  26. Santos ME, Protopopescu C, Sogni P, Yaya I, Piroth L, Bailly F, et al. HCV-related mortality among HIV/HCV co-infected patients: the importance of behaviors in the HCV cure era (ANRS CO13 HEPAVIH Cohort). AIDS Behav. 2020;24(4):1069–84.

    PubMed  Google Scholar 

  27. Hindocha C, Freeman TP, Ferris JA, Lynskey MT, Winstock AR. No smoke without tobacco: a Global overview of cannabis and tobacco routes of administration and their association with intention to quit. Front Psychiatry. 2016. https://doi.org/10.3389/fpsyt.2016.00104/full.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.

    CAS  PubMed  Google Scholar 

  29. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401.

    Google Scholar 

  30. Fuhrer R, Rouillon F. La version française de l’échelle CES-D (Center for Epidemiologic Studies-Depression Scale). Description et traduction de l’échelle d’autoévaluation. Psychiatr Psychobiol. 1989;4(3):163–6.

    Google Scholar 

  31. Rosenthal E, Fougerou-Leurent C, Renault A, Carrieri MP, Marcellin F, Garraffo R, et al. Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). HIV Med. 2018;19(3):227–37.

    CAS  PubMed  Google Scholar 

  32. Justice AC, Holmes W, Gifford AL, Rabeneck L, Zackin R, Sinclair G, et al. Development and validation of a self-completed HIV Symptom Index. J Clin Epidemiol. 2001;54(Suppl 1):S77.

    PubMed  Google Scholar 

  33. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789–95.

    CAS  PubMed  Google Scholar 

  34. Allison PD. Discrete-time methods for the analysis of event histories. Sociol Methodol. 1982;13:61–98.

    Google Scholar 

  35. Butt AA, Yan P, Shuaib A, Abou-Samra A-B, Shaikh OS, Freiberg MS. Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events. Gastroenterology. 2019;156(4):987-996.e8.

    PubMed  Google Scholar 

  36. Midgard H, Hajarizadeh B, Cunningham E, Conway B, Backmund M, Bruggmann P, et al. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: the ACTIVATE study. Int J Drug Policy. 2017;47:230.

    PubMed  Google Scholar 

  37. Juanbeltz R, Martínez-Baz I, Miguel RS, Goñi-Esarte S, Cabasés JM, Castilla J. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS ONE. 2018;13(10):e0205277.

    PubMed  PubMed Central  Google Scholar 

  38. Castera L, Constant A, Bernard P-H, de Ledinghen V, Couzigou P. Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases. World J Gastroenterol. 2006;12(10):1545–50.

    PubMed  PubMed Central  Google Scholar 

  39. Revell AD, Warburton DM, Wesnes K. Smoking as a coping strategy. Addict Behav. 1985;10(3):209–24.

    CAS  PubMed  Google Scholar 

  40. Fidler JA, West R. Self-perceived smoking motives and their correlates in a general population sample. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2009;11(10):1182–8.

    Google Scholar 

  41. Batchelder A, Peyser D, Nahvi S, Arnsten J, Litwin A. “Hepatitis C treatment turned me around:” psychological and behavioral transformation related to hepatitis C treatment. Drug Alcohol Depend. 2015;153:66–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Torrens M, Soyemi T, Bowman D, Schatz E. Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment. BMC Infect Dis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517680/ (2020). Accessed 29 Oct 2020

  43. Williams EB, Nelons D, Seaman A, Witkowska M, Ronan W, Wheelock H, et al. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs. Int J Drug Policy. 2019;72:138–45.

    Google Scholar 

  44. Janda M, Mergenhagen KA. The effect of psychosocial factors on success rates of hepatitis C treatment. Psychosomatics. 2017;58(6):624–32.

    PubMed  Google Scholar 

  45. de Dios MA, Stanton CA, Cano MÁ, Lloyd-Richardson E, Niaura R. The influence of social support on smoking cessation treatment adherence among HIV+ smokers. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2016;18(5):1126–33.

    Google Scholar 

  46. Soulakova JN, Tang C-Y, Leonardo SA, Taliaferro LA. Motivational benefits of social support and behavioural interventions for smoking cessation. J Smok Cessat. 2018;13(4):216–26.

    PubMed  Google Scholar 

  47. Adeyemi OM, Jensen D, Attar B, Ghaoui R, Gallagher M, Wolen D, et al. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDs. 2004;18(4):239–45.

    PubMed  Google Scholar 

  48. Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy. 2016;1(1):2.

    PubMed  PubMed Central  Google Scholar 

  49. Dever JB, Ducom JH, Ma A, Nguyen J, Liu L, Herrin A, et al. Engagement in care of high-risk hepatitis C patients with interferon-free direct-acting antiviral therapies. Dig Dis Sci. 2017;62(6):1472–9.

    PubMed  Google Scholar 

  50. De Socio GV, Ricci E, Maggi P, Orofino G, Squillace N, Menzaghi B, et al. Is it feasible to impact on smoking habits in HIV-Infected patients? Mission impossible from the STOPSHIV Project cohort. J Acquir Immune Defic Syndr 1999. 2020;83:496.

    Google Scholar 

  51. Wray JM, Funderburk JS, Acker JD, Wray LO, Maisto SA. A meta-analysis of brief tobacco interventions for use in integrated primary care. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2018;20(12):1418–26.

    Google Scholar 

  52. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14(4):824–35.

    PubMed  Google Scholar 

  53. Bains M, Britton J, Marsh J, Jayes L, Murray RL. Patients’ and healthcare professionals’ views on a specialist smoking cessation service delivered in a United Kingdom hospital: a qualitative study. Tob Induc Dis. 2014;12(1):2.

    PubMed  PubMed Central  Google Scholar 

  54. Khara M, Okoli C, Nagarajan VD, Aziz F, Hanley C. Smoking cessation outcomes of referral to a specialist hospital outpatient clinic. Am J Addict. 2015;24(6):561–70.

    PubMed  Google Scholar 

  55. Benard A, Bonnet F, Tessier J-F, Fossoux H, Dupon M, Mercie P, et al. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDs. 2007;21(7):458–68.

    PubMed  Google Scholar 

  56. Edwards SK, Dean J, Power J, Baker P, Gartner C. Understanding the prevalence of smoking among people living with HIV (PLHIV) in Australia and factors associated with smoking and quitting. AIDS Behav. 2020;24(4):1056–63.

    PubMed  Google Scholar 

  57. Weinberger AH, Pacek LR, Wall MM, Gbedemah M, Lee J, Goodwin RD. Cigarette smoking quit ratios among adults in the USA with cannabis use and cannabis use disorders, 2002–2016. Tob Control. 2020;29(1):74–80.

    PubMed  Google Scholar 

  58. Voci S, Zawertailo L, Baliunas D, Masood Z, Selby P. Is cannabis use associated with tobacco cessation outcome? An observational cohort study in primary care. Drug Alcohol Depend. 2020;206:107756.

    PubMed  Google Scholar 

  59. Klein MB, Rollet-Kurhajec KC, Moodie EEM, Yaphe S, Tyndall M, Walmsley S, et al. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003–2013). AIDS Lond Engl. 2014;28(13):1957–65.

    Google Scholar 

  60. Agrawal A, Budney AJ, Lynskey MT. The co-occurring use and misuse of cannabis and tobacco: a review. Addict Abingdon Engl. 2012;107(7):1221–33.

    Google Scholar 

  61. McClure EA, Tomko RL, Salazar CA, Akbar SA, Squeglia LM, Herrmann E, et al. Tobacco and cannabis co-use: drug substitution, quit interest, and cessation preferences. Exp Clin Psychopharmacol. 2019;27(3):265–75.

    PubMed  Google Scholar 

  62. Dierker L, Braymiller J, Rose J, Goodwin R, Selya A. Nicotine dependence predicts cannabis use disorder symptoms among adolescents and young adults. Drug Alcohol Depend. 2018;187:212–20.

    PubMed  PubMed Central  Google Scholar 

  63. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol. 2002;13(5–6):451–63.

    CAS  PubMed  Google Scholar 

  64. Rabin RA, George TP. A review of co-morbid tobacco and cannabis use disorders: possible mechanisms to explain high rates of co-use. Am J Addict. 2015;24(2):105–16.

    PubMed  Google Scholar 

  65. Ganzer F, Bröning S, Kraft S, Sack P-M, Thomasius R. Weighing the evidence: a systematic review on long-term neurocognitive effects of Cannabis use in abstinent adolescents and adults. Neuropsychol Rev. 2016;26(2):186–222.

    PubMed  Google Scholar 

  66. Ashare RL, Schmidt HD. Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014;9(6):579–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. McCabe SE, West BT. The three-year course of multiple substance use disorders in the United States: a National Longitudinal Study. J Clin Psychiatry. 2017;78(5):e537–44.

    PubMed  PubMed Central  Google Scholar 

  68. McKelvey K, Thrul J, Ramo D. Impact of quitting smoking and smoking cessation treatment on substance use outcomes: an updated and narrative review. Addict Behav. 2017;65:161–70.

    PubMed  Google Scholar 

  69. Subbaraman MS. Substitution and complementarity of alcohol and Cannabis: a review of the literature. Subst Use Misuse. 2016;51(11):1399–414.

    PubMed  PubMed Central  Google Scholar 

  70. Allsop DJ, Dunlop AJ, Saddler C, Rivas GR, McGregor IS, Copeland J. Changes in cigarette and alcohol use during cannabis abstinence. Drug Alcohol Depend. 2014;138:54–60.

    CAS  PubMed  Google Scholar 

  71. Ducci F, Goldman D. The genetic basis of addictive disorders. Psychiatr Clin North Am. 2012;35(2):495–519.

    PubMed  PubMed Central  Google Scholar 

  72. Loflin M, Earleywine M. No smoke, no fire: What the initial literature suggests regarding vapourized cannabis and respiratory risk. Can J Respir Ther CJRT Rev Can Thérapie Respir RCTR. 2015;51(1):7–9.

    Google Scholar 

  73. Lanz C, Mattsson J, Soydaner U, Brenneisen R. Medicinal Cannabis: In Vitro Validation of vaporizers for the smoke-free inhalation of Cannabis. PLoS ONE 11(1). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718604/ (2016). Accessed 8 Sept 2020

  74. Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, et al. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PLoS ONE. 2018;13(1):e0190768.

    PubMed  PubMed Central  Google Scholar 

  75. Lintzeris N, Bhardwaj A, Mills L, Dunlop A, Copeland J, McGregor I, et al. Nabiximols for the treatment of Cannabis dependence: a randomized clinical trial. JAMA Intern Med. 2019;179:1242.

    PubMed  PubMed Central  Google Scholar 

  76. Lintzeris N, Mills L, Dunlop A, Copeland J, Mcgregor I, Bruno R, et al. Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: results from a placebo-controlled randomised trial. Drug Alcohol Depend. 2020;215:108220.

    CAS  PubMed  Google Scholar 

  77. Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc. 2011;8(3):313–9.

    PubMed  PubMed Central  Google Scholar 

  78. Encrenaz G, Bénard A, Rondeau V, Bonnet F, Lazaro E, Neau D, et al. Determinants of smoking cessation attempts among HIV-infected patients results from a hospital-based prospective cohort. Curr HIV Res. 2010;8(3):212–7.

    CAS  PubMed  Google Scholar 

  79. Weinberger AH, Seng EK, Esan H, Shuter J. Perceived risks and benefits of quitting smoking in a sample of adults living with HIV/AIDS. AIDS Care. 2018;30(5):564–8.

    PubMed  Google Scholar 

  80. Peretti-Watel P, Garelik D, Baron G, Spire B, Ravaud P, Duval X, et al. Smoking motivations and quitting motivations among HIV-infected smokers. Antivir Ther. 2009;14(6):781–7.

    PubMed  Google Scholar 

  81. Chaiton M, Diemert L, Cohen JE, Bondy SJ, Selby P, Philipneri A, et al. Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ Open 6(6). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908897/ (2016). Accessed 14 Jan 2020

  82. Shahab L, Gilchrist G, Hagger-Johnson G, Shankar A, West E, West R. Reciprocal associations between smoking cessation and depression in older smokers: findings from the English Longitudinal Study of Ageing. Br J Psychiatry J Ment Sci. 2015;207(3):243–9.

    Google Scholar 

  83. Harris GE, Dupuis L, Mugford GJ, Johnston L, Haase D, Page G, et al. Patterns and correlates of cannabis use among individuals with HIV/AIDS in Maritime Canada. Can J Infect Dis Med Microbiol. 2014;25(1):e1-7.

    PubMed  PubMed Central  Google Scholar 

  84. Hasin D, Walsh C. Cannabis use, Cannabis use disorder, and comorbid psychiatric illness: a narrative review. J Clin Med. 2020;10(1):15.

    PubMed Central  Google Scholar 

  85. Pacek LR, Towe SL, Hobkirk AL, Nash D, Goodwin RD. Frequency Of Cannabis use and medical cannabis use among persons living with HIV In The United States: findings from a nationally representative sample. AIDS Educ Prev Off Publ Int Soc AIDS Educ. 2018;30(2):169–81.

    Google Scholar 

  86. Regan S, Meigs JB, Grinspoon SK, Triant VA. Determinants of Smoking and Quitting in HIV-Infected Individuals. PLoS ONE 21 11(4). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839777/ (2016). Accessed 7 Nov 2019

Download references

Acknowledgements

This study was sponsored and funded by the French National Agency for Research on Aids and Viral Hepatitis (ANRS). The authors thank all the members of the ANRS-CO-13-HEPAVIH study group. Special thanks to all the physicians and nurses involved in the follow-up of the cohort and all patients who took part in this study. Finally, we thank Jude Sweeney for the English revision and editing of our manuscript.

The ANRS CO13 HEPAVIH Study Group: Scientific Committee: D. Salmon (co-Principal investigator), L. Wittkop (co-Principal Investigator & Methodologist), P. Sogni (co-Principal Investigator), L. Esterle (project manager), P. Trimoulet, J. Izopet, L. Serfaty, V. Paradis, B. Spire, P. Carrieri, M.A. Valantin, G. Pialoux, J. Chas, I. Poizot-Martin, K. Barange, A. Naqvi, E. Rosenthal, A. Bicart-See, O. Bouchaud, A. Gervais, C. Lascoux-Combe, C. Goujard, K. Lacombe, C. Duvivier, D. Neau, P. Morlat, F. Bani-Sadr, L. Meyer, F. Boufassa, B. Autran, A.M. Roque, C. Solas, H. Fontaine, D. Costagliola, L. Piroth, A. Simon, D. Zucman, F. Boué, P. Miailhes, E. Billaud, H. Aumaître, D. Rey, G. Peytavin, V. Petrov-Sanchez, A. Levier. Clinical Centers (ward / participating physicians): APHP, Hôpitaux Universitaires Paris Centre, Paris (Médecine Interne et Maladies Infectieuses: D. Salmon, R. Usubillaga; Hépato-gastro-entérologie: P. Sogni; Anatomo-pathologie: B. Terris; Virologie:P. Tremeaux); APHP Pitié-Salpétrière, Paris (Maladies Infectieuses et Tropicales: C. Katlama, M.A. Valantin, H. Stitou; Médecine Interne: A. Simon, P. Cacoub, S. Nafissa; Hépato-gastro-entérologie: Y. Benhamou; Anatomo-pathologie: F. Charlotte; Virologie: S. Fourati); APHM Sainte-Marguerite, Marseille (Service d'Immuno-Hématologie Clinique : I. Poizot-Martin, O. Zaegel, H. Laroche; Virologie: C. Tamalet); APHP Tenon, Paris (Maladies Infectieuses et Tropicales: G. Pialoux, J. Chas; Anatomo-pathologie: P. Callard, F. Bendjaballah; Virologie: C. Amiel, C. Le Pendeven); CHU Purpan, Toulouse (Maladies Infectieuses et Tropicales: B. Marchou; Médecine interne: L. Alric; Hépato-gastro-entérologie: K. Barange, S. Metivier; Anatomo-pathologie: J. Selves; Virologie: F. Larroquette); CHU Archet, Nice (Médecine Interne: E. Rosenthal; Infectiologie: A. Naqvi, V. Rio; Anatomo-pathologie: J. Haudebourg, M.C. Saint-Paul; Virologie: A. De Monte, V. Giordanengo, C. Partouche); APHP Avicenne, Bobigny (Médecine Interne—Unité VIH: O. Bouchaud; Anatomo-pathologie: A. Martin, M. Ziol; Virologie: Y. Baazia, V. Iwaka-Bande, A. Gerber); Hôpital Joseph Ducuing, Toulouse (Médecine Interne: M. Uzan, A. Bicart-See, D. Garipuy, M.J. Ferro-Collados; Anatomo-pathologie: J. Selves; Virologie: F. Nicot); APHP Bichat—Claude-Bernard, Paris (Maladies Infectieuses:, A. Gervais, Y. Yazdanpanah; Anatomo-pathologie: H. Adle-Biassette; Virologie: G. Alexandre, Pharmacologie: G. Peytavin); APHP Saint-Louis, Paris (Maladies infectieuses: C. Lascoux-Combe, J.M. Molina; Anatomo-pathologie: P. Bertheau; Virologie: M.L. Chaix, C. Delaugerre, S. Maylin); APHP Saint-Antoine (Maladies Infectieuses et Tropicales : K. Lacombe, J. Bottero; J. Krause, P.M. Girard, Anatomo-pathologie : D. Wendum, P. Cervera, J. Adam; Virologie : C. Viala); APHP, Hôpitaux Paris Sud, Bicêtre, Paris (Maladies Infectieuses et Tropicales : D. Vittecocq; Médecine Interne: C. Goujard, Y. Quertainmont, E. Teicher; Virologie: C. Pallier); APHP Necker, Paris (Maladies Infectieuses et Tropicales: O. Lortholary, C. Duvivier, C. Rouzaud, J. Lourenco, F. Touam, C. Louisin: Virologie: V. Avettand-Fenoel, E. Gardiennet, A. Mélard); CHU Bordeaux Hôpital Pellegrin, Bordeaux (Maladies Infectieuses et Tropicales: D. Neau, A. Ochoa, E. Blanchard, S. Castet-Lafarie, C. Cazanave, D. Malvy, M. Dupon, H. Dutronc, F. Dauchy, L. Lacaze-Buzy, A. Desclaux; Anatomo-pathologie: P. Bioulac-Sage; Virologie: P. Trimoulet, S. Reigadas); CHU Bordeaux Hôpital Saint-André, Bordeaux (Médecine Interne et Maladies Infectieuses: P. Morlat, D. Lacoste, F. Bonnet, N. Bernard, M. Hessamfar, J, F. Paccalin, C. Martell, M. C. Pertusa, M. Vandenhende, P. Mercié, D. Malvy, T. Pistone, M.C. Receveur, M. Méchain, P. Duffau, C Rivoisy, I. Faure, S. Caldato; Anatomo-pathologie: P. Bioulac-Sage; Virologie: P. Trimoulet, S. Reigadas, P. Bellecave, C. Tumiotto); CHU Bordeaux Hôpital du Haut-Levêque, Bordeaux (Médecine Interne: J.L. Pellegrin, J.F. Viallard, E. Lazzaro, C. Greib; Anatomo-pathologie: P. Bioulac-Sage; Virologie: P. Trimoulet, S. Reigadas); Hôpital FOCH, Suresnes (Médecine Interne: D. Zucman, C. Majerholc; Virologie: M. Brollo, E. Farfour); APHP Antoine Béclère, Clamart (Médecine Interne: F. Boué, J. Polo Devoto, I. Kansau, V. Chambrin, C. Pignon, L. Berroukeche, R. Fior, V. Martinez, S. Abgrall, M. Favier; Virologie: C. Deback); CHU Henri Mondor, Créteil (Immunologie Clinique: Y. Lévy, S. Dominguez, J.D. Lelièvre, A.S. Lascaux, G. Melica); CHU Nantes Hôpital Hôtel Dieu, Nantes (Maladies Infectieuses et Tropicales: E. Billaud, F. Raffi, C. Allavena , V. Reliquet, D. Boutoille, C. Biron; M. Lefebvre, N. Hall, S. Bouchez; Virologie: A. Rodallec, L. Le Guen, C. Hemon); Hôpital de la Croix Rousse, Lyon (Maladies Infectieuses et Tropicales: P. Miailhes, D. Peyramond, C. Chidiac, F. Ader, F. Biron, A. Boibieux, L. Cotte, T. Ferry, T. Perpoint, J. Koffi, F. Zoulim, F. Bailly, P. Lack, M. Maynard, S. Radenne, M. Amiri, F Valour; Hépato-gastro-entérologie: J. Koffi, F. Zoulim, F. Bailly, P. Lack, M. Maynard, S. Radenne, C. Augustin-Normand; Virologie: C. Scholtes, T.T. Le-Thi); CHU Dijon, Dijon (Département d'infectiologie: L. Piroth, P. Chavanet M. Duong Van Huyen, M. Buisson, A. Waldner-Combernoux, S. Mahy, A. Salmon Rousseau, C. Martins); CH Perpignan, Perpignan (Maladies infectieuses et tropicales: H. Aumaître, Virologie: S. Galim); CHU Robert Debré, Reims (Médecine interne, maladies infectieuses et immunologie clinique: F. Bani-Sadr, D. Lambert, Y Nguyen, J.L. Berger, M. Hentzien, Virologie: V. Brodard); CHRU Strasbourg (Le Trait d’Union: D Rey, M Partisani, ML Batard, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, P.Fischer, Virologie: P Gantner et S Fafi-Kremer). Data collection: F. Roustant, P. Platterier, I. Kmiec, L. Traore, S. Lepuil, S. Parlier, V. Sicart-Payssan, E. Bedel, S. Anriamiandrisoa, C. Pomes, F. Touam, C. Louisin, M. Mole, C. Bolliot, P Catalan, M. Mebarki, A. Adda-Lievin, P. Thilbaut, Y. Ousidhoum, F.Z. Makhoukhi, O. Braik, R. Bayoud, C. Gatey, M.P. Pietri, V. Le Baut, R. Ben Rayana, D. Bornarel, C. Chesnel, D. Beniken, M. Pauchard, S. Akel, S. Caldato, C. Lions, A. Ivanova, A-S. Ritleg, C. Debreux, L. Chalal, J.Zelie, H. Hue, A. Soria, M. Cavellec, S. Breau, A. Joulie, P. Fisher, S. Gohier, D. Croisier-Bertin, S. Ogoudjobi, C. Brochier, V. Thoirain-Galvan, M. Le Cam. Management, statistical analyses: P. Carrieri, M. Chalouni, V. Conte, L. Dequae-Merchadou, M. Desvallees, L. Esterle, C. Gilbert, S. Gillet, R. Knight, T. Lemboub, F. Marcellin, L. Michel, M. Mora, C. Protopopescu, P. Roux, B. Spire, S. Tezkratt, T. Barré, T. Rojas Rojas, M. Baudoin, M. Santos V. Di Beo, M.Nishimwe, L Wittkop.

Funding

This study was sponsored and funded by the French National Agency for Research on Aids and Viral Hepatitis (ANRS).

Author information

Authors and Affiliations

  1. INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, Aix Marseille Univ, Marseille, France

    Tangui Barré, Fabienne Marcellin, Morgane Bureau, Maria Patrizia Carrieri & Camelia Protopopescu

  2. ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d’Azur, Marseille, France

    Tangui Barré

  3. Centre Hospitalier Universitaire (CHU) de Bordeaux, Pôle Médecine Interne, Service de Médecine Interne Et Immunologie Clinique, Bordeaux Population Health Research Center UMR 1219, CIC-EC 1401, Université de Bordeaux, Bordeaux, France

    Patrick Mercié

  4. ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, Université de Bordeaux, Bordeaux, France

    Laure Esterle & Linda Wittkop

  5. Service de Maladies Infectieuses et Tropicales, Centre d’Infectiologie Necker-Pasteur, APHP-Hôpital Necker-Enfants Malades, Paris, France

    Claudine Duvivier

  6. IHU Imagine, Paris, France

    Claudine Duvivier

  7. Institut Cochin–CNRS 8104–INSERM U1016–RIL Team: Retrovirus, Infection and Latency, Université de Paris, Paris, France

    Claudine Duvivier

  8. Centre Médical de L’Institut Pasteur, Institut Pasteur, Paris, France

    Claudine Duvivier

  9. Centre Hépato-Biliaire, AP-HP Hôpital Paul-Brousse, Villejuif, France

    Elina Teicher

  10. DHU Hepatinov, Villejuif, France

    Elina Teicher

  11. Service de Médecine Interne, AP-HP Hôpital Bicêtre, Le Kremlin-Bicêtre, France

    Elina Teicher

  12. Service Maladies Infectieuses et Tropicales, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France

    Julie Chas

  13. Service Maladies Infectieuses et Tropicales, AP-HP, Hôpital Cochin, Paris, France

    Dominique Salmon-Céron

  14. Université Paris Descartes, Paris, France

    Dominique Salmon-Céron & Philippe Sogni

  15. INSERM U1223, Institut Pasteur, Paris, France

    Philippe Sogni

  16. Hôpital Cochin, Paris, France

    Philippe Sogni

  17. Service D’information Médicale, CHU de Bordeaux, Pôle de Santé Publique, Bordeaux, France

    Linda Wittkop

  18. UMR 1252 SESSTIM, Aix-Marseille Univ, Faculté de Médecine, 3e étage - Aile Bleue, 27, boulevard Jean Moulin, 13385, Marseille cedex 5, France

    Fabienne Marcellin

Authors
  1. Tangui Barré
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Mercié
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fabienne Marcellin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laure Esterle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claudine Duvivier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elina Teicher
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Morgane Bureau
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Julie Chas
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dominique Salmon-Céron
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Philippe Sogni
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Maria Patrizia Carrieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Linda Wittkop
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Camelia Protopopescu
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

ANRS CO13 HEPAVIH Study Group

Contributions

TB: study conception, statistical analyses, original draft writing and editing. PM: data collection and draft reviewing and editing. FM: study conception and draft reviewing and editing. LE: data collection and draft reviewing and editing. CD: data collection and draft reviewing and editing. ET: data collection and draft reviewing and editing. MB: draft reviewing and editing. JC: data collection and draft reviewing and editing. DS-C: data collection and draft reviewing and editing. PS: data collection and draft reviewing and editing. MPC: study conception and draft reviewing and editing. LW: data collection, methodological support and draft reviewing and editing. CP: study conception, statistical analyses and draft reviewing and editing.

Corresponding author

Correspondence to Fabienne Marcellin.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare that are relevant to the content of this article.

Ethical Approval

The study was designed and implemented in accordance with the Declaration of Helsinki, and the protocol was approved by the ethics Committee of the Cochin University Hospital in Paris.

Consent to Participate

All participants provided written informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The members of the ANRS CO13 HEPAVIH Study Group are listed in acknowledgement section.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barré, T., Mercié, P., Marcellin, F. et al. HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study). AIDS Behav 25, 4141–4153 (2021). https://doi.org/10.1007/s10461-021-03277-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10461-021-03277-x

Keywords

Search

Navigation